Navigation Links
Anthera Announces First Quarter 2013 Financial Report and Conference Call
Date:5/3/2013

HAYWARD, Calif., May 3, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, will release its first quarter 2013 financial report after market close on Monday, May 13th. Anthera will host a Corporate Update conference call on May 20th, 2013.

Conference Call Access:
Date:   Monday, May 20th, 2013
Time:   5:00 pm Eastern Time

Domestic Dial-in:        (877)312-8807
International Dial-in:   (253)237-1190
Conference ID:           64577060

To access the 24-hour audio replay, U.S. and Canadian participants may dial (855)859-2056; international participants may dial (404)537-3406.  The conference ID for the replay is 64577060. The audio replay will be available until May 27th, 2013. 

About Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases.  Anthera's Phase 3 development product candidate, blisibimod, targets elevated levels of B-cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobin A nephropathy, or IgAN, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia purpura, and others.

CONTACT: Dennis Lutz of Anthera Pharmaceuticals, Inc., dlutz@anthera.com or 510-856-5598.


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amarin, Pharmacyclics, Anthera Pharma, Star Scientific, and Impax Laboratories Under StockCalls Microscope
2. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
3. Anthera Pharmaceuticals Reports 2012 Third Quarter Financial Results And Provides Clinical Progress Update
4. Anthera to Report Second Quarter 2012 Financial Results
5. Life Technologies Announces First Quarter 2013 Results
6. ETEX Corporation announces extended Supply Agreement with Knee Creations, LLC
7. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
8. BioLife Solutions Announces License Agreement
9. PRIM&R Announces Longtime Leader to Step Down
10. MiMedx Announces Record First Quarter 2013 Results
11. ViroPharma Announces First Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... (PRWEB) , ... August 15, 2017 , ... Kapstone ... celebrating 10 years of successes helping medical technology companies and inventors develop and safeguard ... a renowned full-service national engineering firm with a portfolio of clients in the United ...
(Date:8/15/2017)... New York, NY (PRWEB) , ... August 15, 2017 , ... ... for the first time on Immuno-Oncology 360° (IO360°) programming through a series of upcoming ... to be held February 7-9, 2018, at The Roosevelt Hotel in New York City. ...
(Date:8/14/2017)... ... August 14, 2017 , ... The Conference Forum ... which will take place on September 6, 2017 at the Marriott Copley Place in ... of Experimental Medicine, Informatics, and Regulatory Strategy, Pfizer Innovative Research Lab, Pfizer, who leads ...
(Date:8/10/2017)... (PRWEB) , ... August 09, 2017 , ... ... to help the agriculture industry reach its ideal customers with the right message. ... nation. , “As a Midwest company, we realize how crucial the agriculture industry ...
Breaking Biology Technology:
(Date:4/13/2017)... , April 13, 2017 According to a ... Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment ... the IAM Market is expected to grow from USD 14.30 Billion in ... Rate (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
Breaking Biology News(10 mins):